Alzheimer Disease
Conditions
Keywords
Alzheimer Disease, Cerebrospinal fluid, Sleep, Abeta
Brief summary
Introduction: Alzheimer's disease (AD) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (Abeta). Recent animal studies have shown that extended wakefulness is associated with increased production of these Abeta proteins and that sleep leads to a marked fall in their production. Aim: The investigators aim to distinguish a similar effect of sleep disturbance on cerebrospinal fluid (CSF) Abeta levels in humans, which may point out sleep disturbance as an important factor in AD development. Methods: a study in 26 healthy male volunteers, measuring CSF Abeta levels during a sleep deprivation night and before and after a control night with unrestricted sleep. Expected results: The investigators expect sleep deprivation to lead to an increase in CSF Abeta levels, as compared to the levels in the control night.
Interventions
BEHAVIORALSleep deprivation
subjects will undergo one night of full sleep deprivation
Sponsors
University Medical Center Nijmegen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
40 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent * Age 40-60 years * Male * Subject is in good health as established by medical history, physical examination, ECG and laboratory examination * Laboratory parameters (as described on in section 3.7 screening) should be within the normal ranges as applicable in RUNMC, Nijmegen, or clinically acceptable to the investigator * Normal sleep behaviour, Pittsburg Sleep Quality index score ≤5 * MMSE 28 or higher * Medication free
Exclusion criteria
* Presence of blood coagulopathy, established by medical history * Allergy to local anesthetic agents * Contra-indication for spinal catheter placement: medical history of compression of spinal cord, spinal surgery, skin infection, developmental abnormalities in lower spine * Subjects who are currently participating in another study or have participated in a clinical study within 30 days, based on their own report about participation history * Subjects with a history of drug or alcohol abuse * Subjects who are part of the study staff personnel or family members of the study staff personnel
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Amyloid beta | 6 timepoints during one night of sleep deprivation | Subjects will undergo one night of sleep deprivation before, during and after which a total of 9 CSF samples (6ml each) will be drawn through a spinal catheter. From these CSF samples Amyloid beta will be analysed. |
Countries
Netherlands
Outcome results
None listed